4-(甲基磺酰氧基)苯硼酸 | 957035-04-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(甲基磺酰氧基)苯硼酸
• 英文名称: 4-(methanesulfonyloxy)phenylboronic acid
• 英文别名: 4-(methylsulfonyloxy)phenylboronic acid；(4-methylsulfonyloxyphenyl)boronic acid
• CAS: 957035-04-0
• 化学式: C₇H₉BO₅S
• mdl: MFCD09475864
• 分子量: 216.022
• InChiKey: OCARLQIMSVDSQE-UHFFFAOYSA-N

物化性质

• 沸点：
  433.3±51.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  92.2
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2931900090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(Methylsulfonyloxy)phenylboronic acid
Synonyms: 4-Boronophenyl mesylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(Methylsulfonyloxy)phenylboronic acid
CAS number: 957035-04-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H9BO5S
Molecular weight: 216.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(甲基磺酰氧基)苯硼酸 、 3,6-二氢-4-[[(三氟甲基)磺酰]氧基]-1(2H)-吡啶甲酸叔丁酯 在 四(三苯基膦)钯 、 caesium carbonate 作用下， 以 四氢呋喃 、 水 为溶剂， 生成
  参考文献：
  名称：

  使用手性烷氧基胺作为预催化剂对仲醇进行高对映选择性有机催化氧化动力学拆分：催化剂结构、活性物质和底物范围

  摘要：

  描述了使用手性烷氧基胺作为预催化剂的外消旋仲醇的对映选择性有机催化氧化动力学拆分 (OKR) 的开发和表征。已经合成了许多手性烷氧基胺，它们在 OKR 中的结构-对映选择性相关性研究使我们确定了一种有前途的前催化剂，即 7-苄基-3-正丁基-4-氧杂-5-氮杂高金刚烷，它提供了各种手性脂肪族仲醇（ee 高达 >99%，k(rel) 高达 296）。在一项机理研究中，含氯氧铵物种被确定为烷氧基胺预催化剂原位生成的活性物种，并且发现氯原子对于高反应性和对映选择性至关重要。

  DOI：

  10.1021/ja509766f
• 作为产物：
  描述：

  4-(methanesulfonyloxy)phenylboronic pinacol ester 在 盐酸 、 sodium periodate 作用下， 以 水 、 乙腈 为溶剂， 以91 %的产率得到4-(甲基磺酰氧基)苯硼酸
  参考文献：
  名称：

  提高硼酸催化酰胺合成效率的策略

  摘要：

  新型硼酸已被开发用于催化酰胺合成。使用 DFT 进行路易斯酸度估计，并结合收集的动力学数据，可以发现邻（磺酰氧基）苯硼酸，其与现有的最先进的硼酸相比具有优势。获得了脂肪族、芳香族和杂芳香族羧酸以及伯胺和仲胺的有效偶联。

  DOI：

  10.1002/ejoc.202300720

文献信息

• [EN] SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750<br/>[FR] COMPOSÉS 1-CYANOÉTHYLHÉTÉROCYCLYLCARBOXAMIDE SUBSTITUÉS 750
  申请人：ASTRAZENECA AB

  公开号：WO2010128324A1

  公开（公告）日：2010-11-11

  The present invention provides compounds of formula (I), in which y, m, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）的化合物，其中y、m、n、R1、R2和Q如规范中定义，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的用途。
• [EN] SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL]PIPERIDIN-2-YLCARBOXMIDE COMPOUNDS 761<br/>[FR] COMPOSÉS 761 N-[1-CYANO-2-(PHÉNYLE)ÉTHYLE]PIPÉRIDINE-2-YLCARBOXAMIDE SUBSTITUÉS
  申请人：ASTRAZENECA AB

  公开号：WO2010142985A1

  公开（公告）日：2010-12-16

  The present invention provides a compound: (S)-N-((S)-1-Cyano-2-(4-(1-methyl-2-oxoindolin-6-yl)phenyl)ethyl)piperidine-2- carboxamide; (S)-N-((S)-1-Cyano-2-(4-(3-(3-methoxypropyl)-2-oxo-2,3-dihydrobenzo[d]oxazol-5- yl)phenyl)ethyl)piperidine-2-carboxamide; (S)-N-((S)-1-Cyano-2-(4'-(ethylsulfonyl)biphenyl-4-yl)ethyl)piperidine-2-carboxamide; 4'-((S)-2-Cyano-2-((S)-piperidine-2-carboxamido)ethyl)biphenyl-4-yl methanesulfonate; or, (S)-N-((S)-1-Cyano-2-(4-(1-oxoisoindolin-5-yl)phenyl)ethyl)piperidine-2-carboxamide; or a pharmaceutically acceptable salt thereof; a process for its preparation, pharmaceutical compositions containing it and its use in therapy.

  本发明提供了一种化合物：（S）-N-((S)-1-氰基-2-(4-(1-甲基-2-氧基吲哚-6-基)苯基)乙基)哌啶-2-羧酰胺；（S）-N-((S)-1-氰基-2-(4-(3-(3-甲氧丙基)-2-氧基-2,3-二氢苯并[d]噁唑-5- 基)苯基)乙基)哌啶-2-羧酰胺；（S）-N-((S)-1-氰基-2-(4'-(乙磺酰基)联苯基-4-基)乙基)哌啶-2-羧酰胺；4'-((S)-2-氰基-2-((S)-哌啶-2-羧胺基)乙基)联苯基-4-基甲磺酸盐；或者（S）-N-((S)-1-氰基-2-(4-(1-氧基异吲哚-5-基)苯基)乙基)哌啶-2-羧酰胺；或者其药学上可接受的盐；以及其制备方法，含有它的药物组合物以及在治疗中的应用。
• [EN] SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE COMPOUNDS - 760<br/>[FR] COMPOSÉS N-[1-CYANO-2-(PHÉNYL)ÉTHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE SUBSTITUÉS - 760
  申请人：ASTRAZENECA AB

  公开号：WO2011154677A1

  公开（公告）日：2011-12-15

  The present invention provides compounds of formula (I) in which, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）中的化合物，其中n、R1、R2和Q如规范中定义的那样，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的用途。
• Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread
  作者：Manon Garcia、Laurent Hoffer、Raphaël Leblanc、Fatiha Benmansour、Mikael Feracci、Carine Derviaux、Antonio Luis Egea-Jimenez、Philippe Roche、Pascale Zimmermann、Xavier Morelli、Karine Barral

  DOI：10.1016/j.ejmech.2021.113601

  日期：2021.11

  syntenin PDZ domains interacting with syndecans. We therefore aimed to develop, through a fragment-based drug design approach, novel inhibitors targeting syntenin-syndecan interactions. We describe here the optimization of a fragment, ‘hit’ C58, identified by in vitro screening of a PDZ-focused fragment library, which binds specifically to the syntenin-PDZ2 domain at the same binding site as the syndecan-2

  Syntenin 刺激外泌体的产生，其表达在许多癌症中上调，并与转移性肿瘤的扩散有关。这些作用得到了与 Syndecans 相互作用的 Syntenin PDZ 域的支持。因此，我们的目标是通过基于片段的药物设计方法开发针对合成蛋白-合成蛋白聚糖相互作用的新型抑制剂。我们在这里描述了一个片段的优化，“命中” C58，通过体外筛选以 PDZ 为重点的片段库，它与 syntenin-PDZ2 域在与 syndecan-2 肽相同的结合位点特异性结合。X 射线晶体结构和计算对接被用来指导我们的优化过程并导致化合物45和57 (IC 50 = 33 μM 和 47 μM；分别），两个代表的 Syntenin-syndecan 相互作用抑制剂，它们选择性地影响 Syntenin-外泌体的释放。这些发现表明，有可能鉴定出抑制合成蛋白-合成多糖相互作用和外泌体释放的小分子，这些小分子可能对癌症治疗有用。
• SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750
  申请人：Ford Rhonan

  公开号：US20100286118A1

  公开（公告）日：2010-11-11

  The present invention provides compounds of formula (I) in which y, m, n, R 1 , R 2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供式（I）的化合物，其中y，m，n，R1，R2和Q在说明书中定义，以及其制备过程，包含它们的制药组合物和它们在治疗中的使用。